<div><div><h2>Buy Glenmark; target of Rs 790: HDFC Securities</h2></div><div>"hdfc securities' research report on glenmarkglenmark pharma s (gnp) revenue at rs 25.8bn for 2q reported a growth of 14/19% yoy/qoq and beat our estimates by 5%. this was driven by new product launches in the us and traction gained in em and india. ebitda at rs 4.4bn was up 13/27% yoy/qoq with margin remaining largely flat at 17% (in-line). reported pat stood at rs 4.0bn aided by a one-off of rs 1.7bn related to gain in sale of the ortho business and certain write-offs. adjusted for this it came in at rs 2.9bn (+40/28% yoy/qoq).outlookwe estimate a cagr of 8.9% in revenue 9.8% in ebitda and 41.9% in pat with ebitda margin maintained at ~17.5% over fy18-20e. maintain buy with a tp of rs 790 (16x sep-20e eps and rs 135/sh for pipeline).for all recommendations report click heredisclaimer: the views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own and not that of the website or its management. moneycontrol.com advises users to check with certified experts before taking any investment decisions.glenmark_161118"</div></div>